Clinical Trials Logo
  1. Home
  2. Hypercholesterolemia
  3. NCT05421078
  4. Details
NCT05421078 Clinical Trial

A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.

Hypercholesterolemia Clinical Trial

Official title:
A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Dose-Finding Study to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects.

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05421078
Other study ID # TA-8995-203
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date June 27, 2022
Est. completion date August 23, 2023

Study information
Verified date July 2023
Source NewAmsterdam Pharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study in Japanese patients to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to stable statin therapy.

Description:

This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to stable statin therapy in Japanese patients. The screening period for this study will take up to 2-weeks. Afterwards, patients will be randomized to placebo, 2.5 mg obicetrapib, 5 mg obicetrapib or 10 mg obicetrapib for an 8-week treatment period. After the treatment period, patients will continue for a 4-week safety follow-up visit.

Recruitment information / eligibility
Status Completed
Enrollment 108
Est. completion date August 23, 2023
Est. primary completion date April 21, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - LDL-C > 70 mg/dL and TG < 400 mg/dL, - Treated with a stable statin therapy; Atorvastatin 20/40 or Simvastatin 10/20 Exclusion Criteria: - BMI > or =35 kg/m2 - Significant cardiovascular disease - HbA1c > 10% - Uncontrolled hypertension - Active muscle disease - GFR < 60 ml/min - Hepatic dysfunction - Anemia - Existing CETP deficiency - History of Homozygous Familial Hypercholerstrolemia - History of malignancy - Alcohol abuse - Treatment with investigational product - Treatment with PCSK9 - Clinically significant condition - Known CETP inhibitor allergy

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Obicetrapib
tablet
• Obicetrapib
No active ingredient

Locations
Country Name City State
Japan Nippon Kokan Fukuyama Hospital Fukuyama
Japan Nakamura Cardiology and Cardiovascular Surgery Clinic Itoshima
Japan Kishiwada Tokushu-Kai Hospital Osaka
Japan Kyosokai AMC NISHI-UMEDA Clinic Osaka
Japan Sakurabashi Watanabe Hospital Osaka
Japan Uji Tokushu-Kai Hospital Osaka
Japan Sanai Hospital Saitama
Japan Shinden Higashi Clinic Sendai
Japan Soka-Sugiura Clinic Soka
Japan Sugiura Clinic Tokyo

Sponsors (1)
Lead Sponsor Collaborator
NewAmsterdam Pharma

Country where clinical trial is conducted

Japan, 

Outcome
Type Measure Description Time frame Safety issue
Primary LDL-C percent change in LDL-C 8 weeks
Secondary Apo B percent change in Apo B 8 weeks
Secondary Non-HDL-C percent change in Non-HDL-C 8 weeks
Secondary HDL-C percent change in HDL-C 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Recruiting NCT03947866 - Ezetimibe-Rosuvastatin Evaluation Study
Completed NCT01709513 - Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE) Phase 3
Completed NCT01212900 - Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression Phase 4
Completed NCT00001154 - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Completed NCT02550288 - A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383) Phase 3
Completed NCT03929198 - Translation of Pritikin Program to the Community N/A
Completed NCT04485793 - Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia N/A
Completed NCT02341924 - Validating the "Foods for Health" Portfolio of Functional Food Products N/A
Active, not recruiting NCT02223793 - Vascular Lifestyle-Intervention and Screening in Pharmacy N/A
Completed NCT01934608 - The Effect of Synching Prescription Refills on Adherence N/A
Completed NCT01941836 - Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients Phase 2
Recruiting NCT01705873 - Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen N/A
Completed NCT01670734 - Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects Phase 1
Completed NCT01678521 - Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients N/A
Completed NCT01370590 - A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1) Phase 3
Completed NCT01370603 - A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1) Phase 3
Completed NCT01768403 - Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia N/A
Completed NCT01575171 - Using Nudges to Implement Comparative Effectiveness N/A
Completed NCT01446679 - Special Drug Use-Results Survey of Lipitor Tablets N/A